EA201391313A1 - C4-монометилтритерпеноидные производные и способы их применения - Google Patents

C4-монометилтритерпеноидные производные и способы их применения

Info

Publication number
EA201391313A1
EA201391313A1 EA201391313A EA201391313A EA201391313A1 EA 201391313 A1 EA201391313 A1 EA 201391313A1 EA 201391313 A EA201391313 A EA 201391313A EA 201391313 A EA201391313 A EA 201391313A EA 201391313 A1 EA201391313 A1 EA 201391313A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compounds
derivatives
monometiltriterpenoid
application
Prior art date
Application number
EA201391313A
Other languages
English (en)
Other versions
EA026847B1 (ru
Inventor
Эрик Андерсон
Синь Цзян
Мелеэн Висник
Кристофер Ф. Бендер
Сяофэн Лю
Original Assignee
Рита Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рита Фармасьютикалз, Инк. filed Critical Рита Фармасьютикалз, Инк.
Publication of EA201391313A1 publication Critical patent/EA201391313A1/ru
Publication of EA026847B1 publication Critical patent/EA026847B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Abstract

В настоящем описании описаны новые С4-монометилтритерпеноидные соединения и их производные, включающие соединения формулыгде переменные определены в настоящем описании. Также предусматриваются фармацевтические композиции, наборы и изделия, содержащие такие соединения. Также предусматриваются способы и промежуточные соединения, пригодные для получения соединений, и способы применения соединений, например, в качестве антиоксидантных модуляторов воспаления, и их композиций.
EA201391313A 2011-03-11 2012-03-09 C4-монометилтритерпеноидные производные и способы их применения EA026847B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452017P 2011-03-11 2011-03-11
PCT/US2012/028569 WO2012125488A1 (en) 2011-03-11 2012-03-09 C4-monomethyl triterpenoid derivatives and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201391313A1 true EA201391313A1 (ru) 2014-03-31
EA026847B1 EA026847B1 (ru) 2017-05-31

Family

ID=45856041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391313A EA026847B1 (ru) 2011-03-11 2012-03-09 C4-монометилтритерпеноидные производные и способы их применения

Country Status (30)

Country Link
US (1) US9290536B2 (ru)
EP (1) EP2683731B1 (ru)
JP (1) JP6129084B2 (ru)
KR (1) KR101956399B1 (ru)
CN (1) CN103619866B (ru)
AR (1) AR085666A1 (ru)
AU (1) AU2012229244B2 (ru)
BR (1) BR112013023174B1 (ru)
CA (1) CA2829618C (ru)
CL (1) CL2013002612A1 (ru)
CO (1) CO6801741A2 (ru)
CY (1) CY1121744T1 (ru)
DK (1) DK2683731T3 (ru)
EA (1) EA026847B1 (ru)
ES (1) ES2729405T3 (ru)
HR (1) HRP20191164T1 (ru)
HU (1) HUE044081T2 (ru)
IL (1) IL228297B (ru)
LT (1) LT2683731T (ru)
ME (1) ME03469B (ru)
MX (1) MX348862B (ru)
PL (1) PL2683731T3 (ru)
PT (1) PT2683731T (ru)
RS (1) RS59200B1 (ru)
SG (1) SG193404A1 (ru)
SI (1) SI2683731T1 (ru)
TR (1) TR201909788T4 (ru)
TW (1) TWI535731B (ru)
UY (1) UY33946A (ru)
WO (1) WO2012125488A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
WO2009089545A1 (en) 2008-01-11 2009-07-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
CA2731650A1 (en) 2008-07-22 2010-01-28 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
TWI527788B (zh) 2010-12-17 2016-04-01 瑞塔醫藥有限責任公司 作為抗氧化發炎調節劑之吡唑及嘧啶三環烯酮
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
ES2861393T3 (es) 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CN104936972A (zh) * 2012-09-10 2015-09-23 艾伯维公司 具有抗炎活性的甘草次酸衍生物
US9512094B2 (en) * 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CN104768965B (zh) * 2012-09-10 2018-05-11 里亚塔医药公司 齐墩果酸的c17-杂芳基衍生物和其使用方法
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) * 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
EP2977381B1 (en) 2013-03-19 2018-09-26 Daiichi Sankyo Company, Limited Terpenoid derivative
AR096046A1 (es) * 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
CA2814303A1 (en) 2013-04-26 2014-10-26 Cellphone-Mate, Inc. Apparatus and methods for radio frequency signal boosters
CN104861027A (zh) * 2014-02-24 2015-08-26 上海兰蒂斯生物医药科技有限公司 新型齐墩果酸衍生物、其制备方法及其应用
CN104861028A (zh) * 2014-02-24 2015-08-26 上海兰蒂斯生物医药科技有限公司 新型熊果酸衍生物、其制备方法及其应用
ES2770772T3 (es) 2014-09-10 2020-07-03 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación sostenida para el tratamiento y prevención de enfermedades oculares
EA038328B1 (ru) 2015-02-12 2021-08-10 Рита Фармасьютикалз, Инк. Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
US11584775B2 (en) * 2015-09-23 2023-02-21 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
CN105820207A (zh) * 2016-03-24 2016-08-03 庄立 一种茴拉西坦的药物组合物及其抗氧化作用
JP6633812B2 (ja) 2016-11-08 2020-01-22 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2021016191A1 (en) * 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
MX2023008454A (es) 2021-01-18 2023-08-07 Reata Pharmaceuticals Inc Derivados sintéticos de ácido ursólico y métodos de uso de estos.
WO2023156429A1 (en) 2022-02-16 2023-08-24 Firmenich Sa Process for preparing octahydro-2(1h)-naphthalenone derivatives
GB202211190D0 (en) * 2022-08-01 2022-09-14 Royal College Surgeons Ireland Fluorination process

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
CN1361760A (zh) 1999-05-14 2002-07-31 尼瑞斯药品公司 新的白介素－1和肿瘤坏死因子－α调节剂、所述调节剂的合成以及使用所述调节剂的方法
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
WO2002026762A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US20040234977A1 (en) 2001-05-14 2004-11-25 Da-Wei Gong Novel alanine transaminase enzyme and methods of use
AU2003235676A1 (en) 2002-01-15 2003-07-30 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
AU2003205244B2 (en) 2002-01-18 2009-01-08 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
AU2003303128A1 (en) 2002-05-13 2004-08-13 Trustees Of Dartmouth College Inhibitors and methods of use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
CA2579231C (en) 2004-09-07 2018-07-10 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
JP2009530405A (ja) 2006-03-23 2009-08-27 アドバンスト ライフ サイエンシズ インコーポレイテッド 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008000070A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
CN101117348B (zh) 2006-08-01 2010-12-29 浙江海正药业股份有限公司 A环和c环多氧化取代的五环三萜及其制备方法和用途
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
DE13169139T1 (de) 2007-02-08 2022-07-14 Biogen MA Inc. Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US9012439B2 (en) 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
WO2009089545A1 (en) 2008-01-11 2009-07-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
EA022588B1 (ru) * 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
CA2731650A1 (en) 2008-07-22 2010-01-28 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
TR201909743T4 (tr) 2009-02-13 2019-07-22 Reata Pharmaceuticals Inc Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri.
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
CA2795320C (en) 2010-04-12 2019-01-22 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
KR101886467B1 (ko) 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso

Also Published As

Publication number Publication date
JP6129084B2 (ja) 2017-05-17
MX2013010429A (es) 2013-10-03
CA2829618C (en) 2019-07-09
MX348862B (es) 2017-07-03
JP2014508781A (ja) 2014-04-10
US20120252776A1 (en) 2012-10-04
EP2683731A1 (en) 2014-01-15
ES2729405T3 (es) 2019-11-04
PL2683731T3 (pl) 2019-09-30
TR201909788T4 (tr) 2019-07-22
BR112013023174B1 (pt) 2021-09-21
LT2683731T (lt) 2019-07-10
EA026847B1 (ru) 2017-05-31
EP2683731B1 (en) 2019-04-24
SI2683731T1 (sl) 2019-07-31
CL2013002612A1 (es) 2014-05-09
ME03469B (me) 2020-01-20
CN103619866A (zh) 2014-03-05
CY1121744T1 (el) 2020-07-31
SG193404A1 (en) 2013-10-30
RS59200B1 (sr) 2019-10-31
HRP20191164T1 (hr) 2019-10-04
AU2012229244B2 (en) 2017-05-25
HUE044081T2 (hu) 2019-09-30
CN103619866B (zh) 2016-06-22
UY33946A (es) 2012-08-31
DK2683731T3 (da) 2019-06-11
BR112013023174A2 (pt) 2016-08-09
WO2012125488A8 (en) 2013-10-24
KR20140025383A (ko) 2014-03-04
CO6801741A2 (es) 2013-11-29
KR101956399B1 (ko) 2019-03-08
WO2012125488A1 (en) 2012-09-20
PT2683731T (pt) 2019-07-12
CA2829618A1 (en) 2012-09-20
US9290536B2 (en) 2016-03-22
IL228297B (en) 2019-02-28
AU2012229244A1 (en) 2013-10-24
TWI535731B (zh) 2016-06-01
AR085666A1 (es) 2013-10-16
TW201247696A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
EA201390894A1 (ru) Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
CY1121776T1 (el) C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων
CR20140275A (es) Triazolopiridinas sustituidas
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
CR11623A (es) Compuestos
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201590887A1 (ru) Композиция
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
EA201490846A1 (ru) Новые производные арилхинолина
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
EA201591451A1 (ru) Модуляторы flap